Anupam Rasayan Share Price in Focus; To Acquire 100% Stake in US-Based Jayhawk Fine Chemicals

Anupam Rasayan India Ltd has entered into a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals manufacturer, from the CABB Group.  

The company shared transaction details during an investor call on December 15, 2025. Jayhawk is headquartered in Kansas and has been operating in custom and specialty chemicals for several decades. 

Transaction Size and Valuation 

The acquisition has an enterprise value of $134 million, while the total purchase consideration is $150 million. The difference includes cash held on Jayhawk’s balance sheet at the time of acquisition.  

Based on calendar year 2024 numbers, the deal values Jayhawk at an EBITDA multiple of about 9x. 

Funding Structure 

Anupam Rasayan will invest $40 million in the transaction through a mix of internal accruals and debt. The remaining $110 million will be invested by a global investment management firm through Class B non-voting shares.  

This structure allows Anupam Rasayan to retain full equity ownership and consolidate Jayhawk’s financials. 

Jayhawk’s Financial Profile 

Jayhawk reported revenue of around $78 million in CY24, with EBITDA margins close to 19%.  

About 65% of its revenue comes from performance materials, while the rest is linked to life science and related segments. Its customer base spans industries such as semiconductors, aviation, automotive, EVs and electronics. 

Operations and Facilities 

The company operates a manufacturing site in the US spread over nearly 3million square metres. The site includes 2 manufacturing units and a pilot plant used for development and scale-up work. Management indicated that only a part of the available land is currently utilised, leaving room for future expansion. 

Anupam Rasayan Share Price Performance  

As of December 22, 2025, 9:31 am, Anupam Rasayan India share price was trading at ₹1,327.00, a 0.48% decrease from the previous closing price. 

Read More: Fortis Buys People Tree Hospital for ₹430 Crore, Targets 1,500+ Beds in Bengaluru! 

Conclusion 

The company indicated that the transaction is expected to close in January 2026, subject to completion of customary conditions and approvals. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.